Inhibiteurs de la cyclooxygénase 2 : Questions médicales fréquentes
Nom anglais: Cyclooxygenase 2 Inhibitors
Descriptor UI:D052246
Tree Number:D27.505.954.329.030.500.500
Termes MeSH sélectionnés :
Cluster Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cyclooxygénase 2 : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la cyclooxygénase 2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la cyclooxygénase 2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des cyclooxygénases",
"url": "https://questionsmedicales.fr/mesh/D016861",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des cyclooxygénases",
"code": {
"@type": "MedicalCode",
"code": "D016861",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2",
"alternateName": "Cyclooxygenase 2 Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D052246",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Afshin Zarghi",
"url": "https://questionsmedicales.fr/author/Afshin%20Zarghi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Rui Wang",
"url": "https://questionsmedicales.fr/author/Rui%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Mahsa Azami Movahed",
"url": "https://questionsmedicales.fr/author/Mahsa%20Azami%20Movahed",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Mohammad Mahboubi-Rabbani",
"url": "https://questionsmedicales.fr/author/Mohammad%20Mahboubi-Rabbani",
"affiliation": {
"@type": "Organization",
"name": "Islamic Azad University, Tehran Department of Medicinal Chemistry Tehran Iran."
}
},
{
"@type": "Person",
"name": "Ying Wang",
"url": "https://questionsmedicales.fr/author/Ying%20Wang",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Familial caregiving following stroke: findings from the comprehensive post-acute stroke services (COMPASS) pragmatic cluster-randomized transitional care study.",
"datePublished": "2022-05-22",
"url": "https://questionsmedicales.fr/article/35603644",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/10749357.2022.2077520"
}
},
{
"@type": "ScholarlyArticle",
"name": "High Coverage Sub-Nano Iridium Cluster on Core-Shell Cobalt-Cerium Bimetallic Oxide for Highly Efficient Full-pH Water Splitting.",
"datePublished": "2024-10-14",
"url": "https://questionsmedicales.fr/article/39401396",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/advs.202407475"
}
},
{
"@type": "ScholarlyArticle",
"name": "FOXM1 Transcriptionally Co-Upregulates Centrosome Amplification and Clustering Genes and Is a Biomarker for Poor Prognosis in Androgen Receptor-Low Triple-Negative Breast Cancer.",
"datePublished": "2024-09-18",
"url": "https://questionsmedicales.fr/article/39335162",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cancers16183191"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effectiveness and cost-effectiveness of a community intervention in enhancing access to care and improving clinical outcomes for depression: a protocol for a cluster randomised controlled trial in India.",
"datePublished": "2024-08-28",
"url": "https://questionsmedicales.fr/article/39198915",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08236-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cross-Priming-Linked Hierarchical Isothermal Amplification Programming Progressive Activating Clustered Regularly Interspaced Short Palindromic Repeats/Cas12a in miRNA Signaling.",
"datePublished": "2024-08-22",
"url": "https://questionsmedicales.fr/article/39171996",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.analchem.4c02795"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antirhumatismaux",
"item": "https://questionsmedicales.fr/mesh/D018501"
},
{
"@type": "ListItem",
"position": 6,
"name": "Anti-inflammatoires non stéroïdiens",
"item": "https://questionsmedicales.fr/mesh/D000894"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs des cyclooxygénases",
"item": "https://questionsmedicales.fr/mesh/D016861"
},
{
"@type": "ListItem",
"position": 8,
"name": "Inhibiteurs de la cyclooxygénase 2",
"item": "https://questionsmedicales.fr/mesh/D052246"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la cyclooxygénase 2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la cyclooxygénase 2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la cyclooxygénase 2",
"description": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?\nQuels tests sont utilisés pour évaluer l'efficacité des COX-2 ?\nLes COX-2 sont-ils prescrits pour toutes les douleurs ?\nComment différencier les douleurs inflammatoires des autres ?\nQuels signes cliniques indiquent l'utilisation des COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Cluster+Analysis&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels symptômes traitent les inhibiteurs de COX-2 ?\nLes COX-2 soulagent-ils la fièvre ?\nQuels effets secondaires peuvent survenir avec les COX-2 ?\nLes COX-2 affectent-ils l'humeur ?\nPeut-on ressentir des douleurs abdominales avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Cluster+Analysis&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la cyclooxygénase 2",
"description": "Comment prévenir les effets secondaires des COX-2 ?\nY a-t-il des mesures préventives avant de commencer les COX-2 ?\nLes patients à risque doivent-ils éviter les COX-2 ?\nComment surveiller l'efficacité des COX-2 ?\nLes changements de mode de vie aident-ils avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Cluster+Analysis&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels médicaments sont des inhibiteurs de COX-2 ?\nComment les COX-2 sont-ils administrés ?\nLes COX-2 peuvent-ils être combinés avec d'autres médicaments ?\nQuelle est la durée du traitement avec les COX-2 ?\nLes COX-2 sont-ils disponibles sans ordonnance ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Cluster+Analysis&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quelles complications peuvent survenir avec les COX-2 ?\nLes COX-2 augmentent-ils le risque d'accidents vasculaires ?\nComment gérer les complications des COX-2 ?\nLes complications sont-elles fréquentes avec les COX-2 ?\nQuels signes indiquent une complication avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Cluster+Analysis&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?\nL'âge influence-t-il le risque avec les COX-2 ?\nLes femmes enceintes peuvent-elles utiliser des COX-2 ?\nLe tabagisme affecte-t-il l'utilisation des COX-2 ?\nLes antécédents familiaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Cluster+Analysis&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'examen clinique et des tests d'imagerie pour évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des COX-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles de douleur et des tests fonctionnels peuvent être utilisés pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Les COX-2 sont-ils prescrits pour toutes les douleurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont généralement prescrits pour des douleurs inflammatoires spécifiques comme l'arthrite."
}
},
{
"@type": "Question",
"name": "Comment différencier les douleurs inflammatoires des autres ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les douleurs inflammatoires sont souvent accompagnées de raideur matinale et d'enflure."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent l'utilisation des COX-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'enflure, la chaleur et la douleur persistante peuvent indiquer leur utilisation."
}
},
{
"@type": "Question",
"name": "Quels symptômes traitent les inhibiteurs de COX-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils traitent principalement la douleur et l'inflammation associées à des conditions comme l'arthrite."
}
},
{
"@type": "Question",
"name": "Les COX-2 soulagent-ils la fièvre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les inhibiteurs de COX-2 ne sont pas principalement utilisés pour traiter la fièvre."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec les COX-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des troubles gastro-intestinaux, des maux de tête et des vertiges."
}
},
{
"@type": "Question",
"name": "Les COX-2 affectent-ils l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont pas connus pour affecter directement l'humeur, mais la douleur chronique peut le faire."
}
},
{
"@type": "Question",
"name": "Peut-on ressentir des douleurs abdominales avec les COX-2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales peuvent survenir en raison d'effets secondaires gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires des COX-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour prévenir les effets secondaires, il est conseillé de les prendre avec de la nourriture et de suivre les doses prescrites."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant de commencer les COX-2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bilan de santé et une évaluation des antécédents médicaux sont recommandés."
}
},
{
"@type": "Question",
"name": "Les patients à risque doivent-ils éviter les COX-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de problèmes cardiaques doivent consulter un médecin avant de les utiliser."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité des COX-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance peut inclure des évaluations régulières de la douleur et des tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils avec les COX-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer l'efficacité des traitements anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inhibiteurs de COX-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exemples incluent le célécoxib et le rofécoxib, utilisés pour traiter l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les COX-2 sont-ils administrés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par voie orale sous forme de comprimés ou de capsules."
}
},
{
"@type": "Question",
"name": "Les COX-2 peuvent-ils être combinés avec d'autres médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, mais il est important de consulter un médecin pour éviter les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec les COX-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de la condition traitée, mais elle doit être déterminée par un médecin."
}
},
{
"@type": "Question",
"name": "Les COX-2 sont-ils disponibles sans ordonnance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les inhibiteurs de COX-2 nécessitent généralement une prescription médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les COX-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des problèmes gastro-intestinaux, des troubles cardiaques et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les COX-2 augmentent-ils le risque d'accidents vasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains inhibiteurs de COX-2 peuvent augmenter le risque d'accidents vasculaires cérébraux."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des COX-2 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une consultation médicale et un ajustement du traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec les COX-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications ne sont pas fréquentes, mais elles peuvent survenir chez certains patients à risque."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication avec les COX-2 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des saignements gastro-intestinaux ou des éruptions cutanées doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, d'ulcères ou d'allergies augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque avec les COX-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles utiliser des COX-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation des COX-2 pendant la grossesse doit être évitée sauf si prescrite par un médecin."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il l'utilisation des COX-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque de complications gastro-intestinales avec les COX-2."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques peuvent augmenter le risque d'effets secondaires."
}
}
]
}
]
}
Stroke patients discharged home often require prolonged assistance from caregivers. Little is known about the real-world effectiveness of a comprehensive stroke transitional care intervention on relie...
To describe the effect of the COMPASS transitional care (COMPASS-TC) intervention on caregiver strain and characterize the types, duration, and intensity of caregiving....
The cluster-randomized COMPASS pragmatic trial evaluated the effectiveness of COMPASS-TC versus usual care with patients with mild stroke and TIA at 40 hospitals in North Carolina, USA. Of 5882 patien...
1228 caregivers (29%) completed the questionnaire. Completion was positively associated with older patient age, white race, and spousal relationship. One-third of the caregivers provided ≥30 hours of ...
This sample of mild stroke and TIA survivors received significant assistance from familial caregivers. However, caregiver strain was relatively low. Findings support the importance of familial caregiv...
The construction of sub-nanometer cluster catalysts (<1 nm) with almost complete exposure of active atoms serves as a promising avenue for the simultaneous enhancement of atom utilization efficiency a...
Although depression is the leading cause of disability worldwide, treatment coverage for the condition is inadequate. Supply-side barriers (e.g. shortage of specialist mental health professionals) and...
A hybrid type 2 effectiveness implementation cluster randomised controlled trial will be implemented in the state of Goa, India. Twenty-eight clusters of villages and their associated public sector he...
If effective, our community intervention will have relevance to India's Ayushman Bharat universal healthcare programme which is scaling up care for depression in primary care, and also to other low- a...
Registered on ClincalTrials.gov ( NCT05890222 .) on 12/05/2023....
Cascade isothermal nucleic acid amplification, which integrates several different amplification protocols to enhance the assay performance, is widely utilized in biosensing, particularly for detecting...
The Puccinia graminis f. sp. tritici (Pgt) Ug99-emerging virulent races present a major challenge to global wheat production. To meet present and future needs, new sources of resistance must be found....
In the UK, recent evidence of young people and gambling indicates a higher prevalence of gambling in comparison to other addictive behaviours. Engaging in gambling-related behaviour at a young age is ...
Pilot cluster RCT with an embedded process evaluation and health economic scoping study....
PRoGRAM-A will be delivered in four schools, with two control schools acting as a comparator. All are secondary schools in Scotland. Baseline surveys were conducted with students in S3 (ages 13-14). F...
PRoGRAM-A trainers will deliver a 2-day, out-of-school training workshop to Peer supporters. Peer supporters will be nominated by peers among their school year group (S3, age 13-14). Workshops will pr...
The primary outcome of the pilot cluster RCT (cRCT) will be whether progression to a phase III RCT is justified....
This will be the first pilot cluster RCT (cRCT) of an intervention to prevent gambling-related harms among young people within the UK. If findings indicate feasibility and acceptability, funding will ...
Researchregistry8699. Registered 21...
High efficiently photocatalytic CO2 reduction (CO2RR) into liquid fuels in pure water system remains challenged. Iron polyphthalocyanine (FePPc) with strong light harvesting, unique Fe-N4 structure, a...
To evaluate the effectiveness of a clinical decision support system (CDSS) in improving the use of guideline accordant antihypertensive treatment in primary care settings in China....
Pragmatic, open label, cluster randomised trial....
94 primary care practices in four urban regions of China between August 2019 and July 2022: Luoyang (central China), Jining (east China), and Shenzhen (south China, including two regions)....
94 practices were randomised (46 to CDSS, 48 to usual care). 12 137 participants with hypertension who used up to two classes of antihypertensives and had a systolic blood pressure <180 mm Hg and dias...
Primary care practices were randomised to use an electronic health record based CDSS, which recommended a specific guideline accordant regimen for initiation, titration, or switching of antihypertensi...
The primary outcome was the proportion of hypertension related visits during which an appropriate (guideline accordant) treatment was provided. Secondary outcomes were the average reduction in systoli...
5755 participants with 23 113 visits in the intervention group and 6382 participants with 27 868 visits in the control group were included. Mean age was 61 (standard deviation 13) years and 42.5% were...
Use of a CDSS in primary care in China improved the provision of guideline accordant antihypertensive treatment and led to a modest reduction in blood pressure. The CDSS offers a promising approach to...
ClinicalTrials.gov NCT03636334....
To examine behavior changes among formal caregivers in Taiwanese long-term care facilities (LTCFs) after receiving training in function-focused care for cognitive impairment (FFC-CI)....
The current study was a clustered randomized controlled trial. Formal caregivers (i.e., RNs and nursing assistants) (...
Statistically significant changes were noted in each activity of restorative care behavior among the four observational measurements. Results also indicated that job satisfaction was a statistically s...
To eliminate gaps between translating research outcomes to clinical practice, this study applied a theory-based caring model for caregivers to improve knowledge and skills in caring for older adults w...